With the rapid development of the biomedical field, there is a growing demand for precision and individualization of disease models. Against this background, the iHuPDX model developed by InnoModels Biotechnology has become a shining star in the field of drug efficacy evaluation due to its unique individualized features and excellent stability. In this paper, we will introduce the features of iHuPDX model in depth and lead readers to explore its unlimited potential in pharmaceutical research.
First of all, the iHuPDX model is a xenotransplantation technique based on individual patient tumor cells. This technology forms highly individualized transplanted tumors by collecting cancer tissue samples from patients and transplanting them into animals such as mice. This model not only simulates the real growth environment of the patient's tumor, but also preserves the original biological characteristics of the tumor cells, making the experimental results closer to the actual situation of the patient. Therefore, iHuPDX model plays a pivotal role in the development of precision medicine and personalized treatment plans.
Secondly, iHuPDX model has highly individualized characteristics. Each patient's tumor cells are unique, so the iHuPDX model based on individual patient tumor cells can restore the patient's tumor characteristics to the greatest extent. This individualization feature allows the model to excel in drug response prediction. With the iHuPDX model, researchers can test the response of different drugs to a specific patient's tumor, thereby tailoring a personalized treatment plan for the patient. This precise treatment approach is expected to significantly increase the success rate of treatment, reduce side effects and improve patients' quality of life.

In addition, the iHuPDX model has excellent stability and growth rate. With advanced primary cell inoculation technology, the model is able to achieve early and uniform growth, ensuring that efficacy experiments are conducted within the optimal window. At the same time, the homogenization of the same batch of samples is ensured through the cell suspension modeling approach, resulting in a high degree of consistency in the growth rate and biological characteristics of the model. This stability not only ensures the reliability of the experimental results, but also reduces the experimental and time costs, providing researchers with a more efficient and convenient experimental platform.
Finally, it is worth mentioning that the iHuPDX model also provides a new perspective for cancer research. With the help of this highly individualized disease model, researchers can explore more deeply the differences in tumor heterogeneity among different patients and reveal the diversity of cancers. This will help us better understand the mechanisms of cancer occurrence and provide important information for the development of individualized treatment strategies.
In summary, the iHuPDX model of InnoModels Biotechnology has shown great potential and value in the field of drug efficacy evaluation by virtue of its individualized features, excellent stability and growth rate, and the new perspective it provides for cancer research. With the continuous development and improvement of the technology, it is believed that the iHuPDX model will bring benefits to more patients in the future, and drive the biomedical field towards a new era of greater precision and efficiency.